TC
RNA icon

Trium Capital’s Atrium Therapeutics RNA Stock Holding History

Trium Capital’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$483K Sell
58,382
-54,896
-48% -$648K 0.61% 24
2026
Q2 		$1.52M Buy
+113,278
New +$1.48M 0.94% 20

Other funds holding RNA

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FIA
FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Trium Capital's RNA Position: Q3 2026 in Review

Trium Capital reduced its Atrium Therapeutics (RNA) stake by 48% in Q3 2026, selling an estimated $648K and leaving 58,382 shares worth $483K. The position accounts for 0.61% of the portfolio, ranked #24.

Trium Capital first reported a position in RNA in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.52M in Q2 2026. 9 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Trium Capital held 58,382 shares of Atrium Therapeutics worth $483K as of Q3 2026.
  • Trium Capital sold 54,896 Atrium Therapeutics shares in Q3 2026, an estimated $648K.
  • Atrium Therapeutics made up 0.61% of Trium Capital's portfolio in Q3 2026, its #24 holding.
  • Trium Capital first reported a position in Atrium Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Trium Capital's Atrium Therapeutics position peaked at $1.52M in Q2 2026.
  • 9 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Trium Capital's 13F filing for Q3 2026, filed 16 Oct 2026.